PA-GROVARA
19.5.2022 13:02:12 CEST | Business Wire | Press release
Grovara , the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC) , a permanent wholesale market that facilitates business between international buyers and sellers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/
The partnership will integrate Grovara’s first-to-market digital global trading platform with DGC’s one-of-a-kind physical marketplace, providing unprecedented speed, reliability, and growth potential for DGC’s global wholesale buyers and sellers.
Grovara will leverage its international B2B online marketplace with DGC’s state-of-the-art showroom ecosystem for wholesale food, home furnishings, and fashion trade to supercharge CPG brands’ global distribution. Grovara’s digital platform streamlines and automates global wholesale trade, enabling buyers to find and manage suppliers and sellers while showcasing and selling goods online and managing fulfillment.
“The future of trade is digital, with a human touch. Our game-changing global marketplace will help bring Dubai Global Connect’s community of brands and buyers online,” says Grovara Co-Founder and CEO Abu Kamara. “Our technology is a turbo booster for international trade, and coupled with DGC’s state-of-the-art, bespoke physical showroom marketplace, Dubai is ready to be the launch pad.”
DGC’s facility will be one of the highlights of fast-growing Dubai South, the largest single urban master development in Dubai. Dubai South is being developed as an aviation and logistics ecosystem including a multi-modal transport infrastructure connecting air, land, and sea, and planned residential and commercial developments. DGC is located between Al Maktoum International Airport, which will be the world’s largest airport when construction is complete, and Jebel Ali Port, the Middle East’s busiest port.
With 2.5 billion people within a four-hour flight and 5 billion within an eight-hour flight, Dubai is globally recognized as an ideal place to live, work and play, while also offering transparent, business-friendly free-zone regulation across the country. The Dubai South Free Zone fosters ingenuity, offers ease of doing business, and provides comprehensive services that enable 100% foreign ownership and income and personal tax exemption.
Grovara will be the digital global wholesale option for those new businesses looking for buyers and sellers, with easy discovery, pricing, and purchasing that saves time and cost while delivering better performance via a curated marketplace. Sellers rely on Grovara’s automated export and operations document managers and achieve faster sales and brand valuations by selling to more customers.
“Our technology and in-country expertise will make it even easier for buyers and sellers from across the entire region to meet halfway in Dubai, where they’ll find all the support they need to grow,” says Grovara Sales Director Eugenia Schlitter.
DGC offers a number of physical spaces and services for brands and buyers, like showrooms, boutique offices, secure self-storage units with direct access to showrooms, and a smart service center offering a one-stop shop for a variety of business services. DGC is also planning a lavish auditorium, innovation hub, entrepreneurship center, and a year-round program of industry-specific programming.
“We are pleased to welcome Grovara to the Dubai Global Connect community here in Dubai,” says DGC’s Head of Business Development Paul Boots. “Grovara will be able to tap into DGC’s year-round physical showroom ecosystem and showcase some of the great brands available on their platform.
“Dubai is the natural gateway to the emerging markets, and the combination of Grovara and DGC will enable brands to expand their reach to a global buying audience, through Dubai. Partnerships such as these will further support DGC’s ambition to make Dubai a place of reference for the international B2B food trade, and we look forward to supporting them with the growth of their business.”
ABOUT GROVARA
Grovara enables an easy global wholesale experience as the first-to-market online marketplace supporting thousands of CPG products for export/import in more than 50 countries. With offices in Philadelphia, Mexico, and Dubai, Grovara facilitates global exporting and importing with a lightweight, tech-driven platform that provides automation and intelligence-based tools. Grovara leverages visibility, discovery, and an intuitive user experience to deliver easy transacting and management, creating a streamlined pathway to dynamic global growth potential. For more information or to join the curated ecosystem, please visit Grovara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom